TriangleNCT01943851 · OUTCOME
Part 1: Number of Participants With Grade Change From Baseline in Hematology Parameters
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- COUNT_OF_PARTICIPANTS
- Unit
- Participants
- Interval / dispersion
- Not reported
- Time frame
- Up to 86.9 weeks
What was measured
Blood samples were collected for the analysis of following hematology parameters: hemoglobin, lymphocytes, neutrophils, platelets and leukocytes. The laboratory parameters were graded according to NCI-CTCAE version 4.0. Grade 1: mild; Grade 2: moderate; Grade 3: severe or medically significant; Grade 4: life-threatening consequences; Grade 5: death related to AE. Higher grade indicates greater severity. An increase is defined as an increase in CTCAE grade relative to Baseline grade. Baseline was the most recent, non-missing value prior to or on the first study treatment dose date. Data for worst-case post Baseline with any grade increase is presented.
Analysis population: All Treated Population. Only those participants with data available at the specified data points were analyzed (represented by n=X in category titles).
Groups in this outcome
Part 1: GSK525762 5 mg QD
Participants were administered once daily oral dose of 5 milligrams (mg) GSK525762.
Part 1: GSK525762 10 mg QD
Participants were administered once daily oral dose of 10 mg GSK525762.
Part 1: GSK525762 20 mg QD
Participants were administered once daily oral dose of 20 mg GSK525762.
Part 1: GSK525762 30 mg QD MM
Participants with multiple myeloma (MM) were administered once daily oral dose of 30 mg GSK525762.
Part 1: GSK525762 40 mg QD
Participants were administered once daily oral dose of 40 mg GSK525762.
Part 1: GSK525762 40 mg QD MM
Participants with multiple myeloma were administered once daily oral dose of 40 mg GSK525762.
Part 1: GSK525762 60 mg QD AML
Participants with Acute Myeloid Leukemia (AML) were administered once daily oral dose of 60 mg GSK525762.
Part 1: GSK525762 60 mg QD NHL
Participants with Non-Hodgkin's Lymphoma (NHL) were administered once daily oral dose of 60 mg GSK525762.
Part 1: GSK525762 60 mg QD MM
Participants with MM were administered once daily oral dose of 60 mg GSK525762.
Part 1: GSK525762 75 mg QD AML
Participants with AML were administered once daily oral dose of 75 mg GSK525762.
Part 1: GSK525762 80 mg QD
Participants were administered once daily oral dose of 80 mg GSK525762.
Part 1: GSK525762 80 mg QD AML
Participants with AML were administered once daily oral dose of 80 mg GSK525762.
Part 1: GSK525762 80 mg QD NHL
Participants with NHL were administered once daily oral dose of 80 mg GSK525762.
Part 1: GSK525762 100 mg QD AML
Participants with AML were administered once daily oral dose of 100 mg GSK525762.
Part 1: GSK525762 120 mg QD AML
Participants with AML were administered once daily oral dose of 120 mg GSK525762.
| Group | Source count |
|---|---|
| Part 1: GSK525762 5 mg QD | 1 |
| Part 1: GSK525762 10 mg QD | 1 |
| Part 1: GSK525762 20 mg QD | 1 |
| Part 1: GSK525762 30 mg QD MM | 5 |
| Part 1: GSK525762 40 mg QD | 1 |
| Part 1: GSK525762 40 mg QD MM | 4 |
| Part 1: GSK525762 60 mg QD AML | 7 |
| Part 1: GSK525762 60 mg QD NHL | 18 |
| Part 1: GSK525762 60 mg QD MM | 3 |
| Part 1: GSK525762 75 mg QD AML | 8 |
| Part 1: GSK525762 80 mg QD | 1 |
| Part 1: GSK525762 80 mg QD AML | 7 |
| Part 1: GSK525762 80 mg QD NHL | 7 |
| Part 1: GSK525762 100 mg QD AML | 16 |
| Part 1: GSK525762 120 mg QD AML | 6 |
Reported measurements
Hemoglobin, n=1,1,1,5,1,4,7,18,3,8,1,7,7,16,6
| Group | Source count |
|---|---|
| Part 1: GSK525762 5 mg QD | 1 |
| Part 1: GSK525762 10 mg QD | 1 |
| Part 1: GSK525762 20 mg QD | 1 |
| Part 1: GSK525762 30 mg QD MM | 5 |
| Part 1: GSK525762 40 mg QD | 1 |
| Part 1: GSK525762 40 mg QD MM | 4 |
| Part 1: GSK525762 60 mg QD AML | 7 |
| Part 1: GSK525762 60 mg QD NHL | 18 |
| Part 1: GSK525762 60 mg QD MM | 3 |
| Part 1: GSK525762 75 mg QD AML | 8 |
| Part 1: GSK525762 80 mg QD | 1 |
| Part 1: GSK525762 80 mg QD AML | 7 |
| Part 1: GSK525762 80 mg QD NHL | 7 |
| Part 1: GSK525762 100 mg QD AML | 16 |
| Part 1: GSK525762 120 mg QD AML | 6 |
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Part 1: GSK525762 5 mg QD | 1 | Not reported | Not reported | Not reported | Not reported |
| Part 1: GSK525762 10 mg QD | 0 | Not reported | Not reported | Not reported | Not reported |
| Part 1: GSK525762 20 mg QD | 0 | Not reported | Not reported | Not reported | Not reported |
| Part 1: GSK525762 30 mg QD MM | 2 | Not reported | Not reported | Not reported | Not reported |
| Part 1: GSK525762 40 mg QD | 0 | Not reported | Not reported | Not reported | Not reported |
| Part 1: GSK525762 40 mg QD MM | 2 | Not reported | Not reported | Not reported | Not reported |
| Part 1: GSK525762 60 mg QD AML | 3 | Not reported | Not reported | Not reported | Not reported |
| Part 1: GSK525762 60 mg QD NHL | 13 | Not reported | Not reported | Not reported | Not reported |
| Part 1: GSK525762 60 mg QD MM | 3 | Not reported | Not reported | Not reported | Not reported |
| Part 1: GSK525762 75 mg QD AML | 6 | Not reported | Not reported | Not reported | Not reported |
| Part 1: GSK525762 80 mg QD | 1 | Not reported | Not reported | Not reported | Not reported |
| Part 1: GSK525762 80 mg QD AML | 4 | Not reported | Not reported | Not reported | Not reported |
| Part 1: GSK525762 80 mg QD NHL | 6 | Not reported | Not reported | Not reported | Not reported |
| Part 1: GSK525762 100 mg QD AML | 9 | Not reported | Not reported | Not reported | Not reported |
| Part 1: GSK525762 120 mg QD AML | 3 | Not reported | Not reported | Not reported | Not reported |
Lymphocytes, n=1,1,0,5,1,4,7,18,3,8,1,7,7,15,6
| Group | Source count |
|---|---|
| Part 1: GSK525762 5 mg QD | 1 |
| Part 1: GSK525762 10 mg QD | 1 |
| Part 1: GSK525762 20 mg QD | 0 |
| Part 1: GSK525762 30 mg QD MM | 5 |
| Part 1: GSK525762 40 mg QD | 1 |
| Part 1: GSK525762 40 mg QD MM | 4 |
| Part 1: GSK525762 60 mg QD AML | 7 |
| Part 1: GSK525762 60 mg QD NHL | 18 |
| Part 1: GSK525762 60 mg QD MM | 3 |
| Part 1: GSK525762 75 mg QD AML | 8 |
| Part 1: GSK525762 80 mg QD | 1 |
| Part 1: GSK525762 80 mg QD AML | 7 |
| Part 1: GSK525762 80 mg QD NHL | 7 |
| Part 1: GSK525762 100 mg QD AML | 15 |
| Part 1: GSK525762 120 mg QD AML | 6 |
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Part 1: GSK525762 5 mg QD | 0 | Not reported | Not reported | Not reported | Not reported |
| Part 1: GSK525762 10 mg QD | 0 | Not reported | Not reported | Not reported | Not reported |
| Part 1: GSK525762 30 mg QD MM | 3 | Not reported | Not reported | Not reported | Not reported |
| Part 1: GSK525762 40 mg QD | 1 | Not reported | Not reported | Not reported | Not reported |
| Part 1: GSK525762 40 mg QD MM | 3 | Not reported | Not reported | Not reported | Not reported |
| Part 1: GSK525762 60 mg QD AML | 4 | Not reported | Not reported | Not reported | Not reported |
| Part 1: GSK525762 60 mg QD NHL | 11 | Not reported | Not reported | Not reported | Not reported |
| Part 1: GSK525762 60 mg QD MM | 2 | Not reported | Not reported | Not reported | Not reported |
| Part 1: GSK525762 75 mg QD AML | 5 | Not reported | Not reported | Not reported | Not reported |
| Part 1: GSK525762 80 mg QD | 1 | Not reported | Not reported | Not reported | Not reported |
| Part 1: GSK525762 80 mg QD AML | 6 | Not reported | Not reported | Not reported | Not reported |
| Part 1: GSK525762 80 mg QD NHL | 3 | Not reported | Not reported | Not reported | Not reported |
| Part 1: GSK525762 100 mg QD AML | 10 | Not reported | Not reported | Not reported | Not reported |
| Part 1: GSK525762 120 mg QD AML | 5 | Not reported | Not reported | Not reported | Not reported |
Neutrophils, n=1,1,0,5,1,4,7,18,3,8,1,7,7,15,5
| Group | Source count |
|---|---|
| Part 1: GSK525762 5 mg QD | 1 |
| Part 1: GSK525762 10 mg QD | 1 |
| Part 1: GSK525762 20 mg QD | 0 |
| Part 1: GSK525762 30 mg QD MM | 5 |
| Part 1: GSK525762 40 mg QD | 1 |
| Part 1: GSK525762 40 mg QD MM | 4 |
| Part 1: GSK525762 60 mg QD AML | 7 |
| Part 1: GSK525762 60 mg QD NHL | 18 |
| Part 1: GSK525762 60 mg QD MM | 3 |
| Part 1: GSK525762 75 mg QD AML | 8 |
| Part 1: GSK525762 80 mg QD | 1 |
| Part 1: GSK525762 80 mg QD AML | 7 |
| Part 1: GSK525762 80 mg QD NHL | 7 |
| Part 1: GSK525762 100 mg QD AML | 15 |
| Part 1: GSK525762 120 mg QD AML | 5 |
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Part 1: GSK525762 5 mg QD | 0 | Not reported | Not reported | Not reported | Not reported |
| Part 1: GSK525762 10 mg QD | 0 | Not reported | Not reported | Not reported | Not reported |
| Part 1: GSK525762 30 mg QD MM | 4 | Not reported | Not reported | Not reported | Not reported |
| Part 1: GSK525762 40 mg QD | 0 | Not reported | Not reported | Not reported | Not reported |
| Part 1: GSK525762 40 mg QD MM | 3 | Not reported | Not reported | Not reported | Not reported |
| Part 1: GSK525762 60 mg QD AML | 1 | Not reported | Not reported | Not reported | Not reported |
| Part 1: GSK525762 60 mg QD NHL | 6 | Not reported | Not reported | Not reported | Not reported |
| Part 1: GSK525762 60 mg QD MM | 2 | Not reported | Not reported | Not reported | Not reported |
| Part 1: GSK525762 75 mg QD AML | 5 | Not reported | Not reported | Not reported | Not reported |
| Part 1: GSK525762 80 mg QD | 0 | Not reported | Not reported | Not reported | Not reported |
| Part 1: GSK525762 80 mg QD AML | 2 | Not reported | Not reported | Not reported | Not reported |
| Part 1: GSK525762 80 mg QD NHL | 5 | Not reported | Not reported | Not reported | Not reported |
| Part 1: GSK525762 100 mg QD AML | 3 | Not reported | Not reported | Not reported | Not reported |
| Part 1: GSK525762 120 mg QD AML | 1 | Not reported | Not reported | Not reported | Not reported |
Platelets, n=1,1,1,5,1,4,7,18,3,8,1,7,7,16,6
| Group | Source count |
|---|---|
| Part 1: GSK525762 5 mg QD | 1 |
| Part 1: GSK525762 10 mg QD | 1 |
| Part 1: GSK525762 20 mg QD | 1 |
| Part 1: GSK525762 30 mg QD MM | 5 |
| Part 1: GSK525762 40 mg QD | 1 |
| Part 1: GSK525762 40 mg QD MM | 4 |
| Part 1: GSK525762 60 mg QD AML | 7 |
| Part 1: GSK525762 60 mg QD NHL | 18 |
| Part 1: GSK525762 60 mg QD MM | 3 |
| Part 1: GSK525762 75 mg QD AML | 8 |
| Part 1: GSK525762 80 mg QD | 1 |
| Part 1: GSK525762 80 mg QD AML | 7 |
| Part 1: GSK525762 80 mg QD NHL | 7 |
| Part 1: GSK525762 100 mg QD AML | 16 |
| Part 1: GSK525762 120 mg QD AML | 6 |
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Part 1: GSK525762 5 mg QD | 0 | Not reported | Not reported | Not reported | Not reported |
| Part 1: GSK525762 10 mg QD | 0 | Not reported | Not reported | Not reported | Not reported |
| Part 1: GSK525762 20 mg QD | 1 | Not reported | Not reported | Not reported | Not reported |
| Part 1: GSK525762 30 mg QD MM | 4 | Not reported | Not reported | Not reported | Not reported |
| Part 1: GSK525762 40 mg QD | 1 | Not reported | Not reported | Not reported | Not reported |
| Part 1: GSK525762 40 mg QD MM | 4 | Not reported | Not reported | Not reported | Not reported |
| Part 1: GSK525762 60 mg QD AML | 4 | Not reported | Not reported | Not reported | Not reported |
| Part 1: GSK525762 60 mg QD NHL | 17 | Not reported | Not reported | Not reported | Not reported |
| Part 1: GSK525762 60 mg QD MM | 3 | Not reported | Not reported | Not reported | Not reported |
| Part 1: GSK525762 75 mg QD AML | 4 | Not reported | Not reported | Not reported | Not reported |
| Part 1: GSK525762 80 mg QD | 1 | Not reported | Not reported | Not reported | Not reported |
| Part 1: GSK525762 80 mg QD AML | 5 | Not reported | Not reported | Not reported | Not reported |
| Part 1: GSK525762 80 mg QD NHL | 7 | Not reported | Not reported | Not reported | Not reported |
| Part 1: GSK525762 100 mg QD AML | 11 | Not reported | Not reported | Not reported | Not reported |
| Part 1: GSK525762 120 mg QD AML | 2 | Not reported | Not reported | Not reported | Not reported |
Leukocytes, n=1,1,1,5,1,4,7,18,3,8,1,7,7,16,6
| Group | Source count |
|---|---|
| Part 1: GSK525762 5 mg QD | 1 |
| Part 1: GSK525762 10 mg QD | 1 |
| Part 1: GSK525762 20 mg QD | 1 |
| Part 1: GSK525762 30 mg QD MM | 5 |
| Part 1: GSK525762 40 mg QD | 1 |
| Part 1: GSK525762 40 mg QD MM | 4 |
| Part 1: GSK525762 60 mg QD AML | 7 |
| Part 1: GSK525762 60 mg QD NHL | 18 |
| Part 1: GSK525762 60 mg QD MM | 3 |
| Part 1: GSK525762 75 mg QD AML | 8 |
| Part 1: GSK525762 80 mg QD | 1 |
| Part 1: GSK525762 80 mg QD AML | 7 |
| Part 1: GSK525762 80 mg QD NHL | 7 |
| Part 1: GSK525762 100 mg QD AML | 16 |
| Part 1: GSK525762 120 mg QD AML | 6 |
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Part 1: GSK525762 5 mg QD | 0 | Not reported | Not reported | Not reported | Not reported |
| Part 1: GSK525762 10 mg QD | 0 | Not reported | Not reported | Not reported | Not reported |
| Part 1: GSK525762 20 mg QD | 1 | Not reported | Not reported | Not reported | Not reported |
| Part 1: GSK525762 30 mg QD MM | 4 | Not reported | Not reported | Not reported | Not reported |
| Part 1: GSK525762 40 mg QD | 1 | Not reported | Not reported | Not reported | Not reported |
| Part 1: GSK525762 40 mg QD MM | 3 | Not reported | Not reported | Not reported | Not reported |
| Part 1: GSK525762 60 mg QD AML | 2 | Not reported | Not reported | Not reported | Not reported |
| Part 1: GSK525762 60 mg QD NHL | 9 | Not reported | Not reported | Not reported | Not reported |
| Part 1: GSK525762 60 mg QD MM | 3 | Not reported | Not reported | Not reported | Not reported |
| Part 1: GSK525762 75 mg QD AML | 4 | Not reported | Not reported | Not reported | Not reported |
| Part 1: GSK525762 80 mg QD | 1 | Not reported | Not reported | Not reported | Not reported |
| Part 1: GSK525762 80 mg QD AML | 3 | Not reported | Not reported | Not reported | Not reported |
| Part 1: GSK525762 80 mg QD NHL | 4 | Not reported | Not reported | Not reported | Not reported |
| Part 1: GSK525762 100 mg QD AML | 9 | Not reported | Not reported | Not reported | Not reported |
| Part 1: GSK525762 120 mg QD AML | 3 | Not reported | Not reported | Not reported | Not reported |
Complete source fields
- classes
- categories
- measurements
- group Id
- OG000
- value
- 1
- group Id
- OG001
- value
- 0
- group Id
- OG002
- value
- 0
- group Id
- OG003
- value
- 2
- group Id
- OG004
- value
- 0
- group Id
- OG005
- value
- 2
- group Id
- OG006
- value
- 3
- group Id
- OG007
- value
- 13
- group Id
- OG008
- value
- 3
- group Id
- OG009
- value
- 6
- group Id
- OG010
- value
- 1
- group Id
- OG011
- value
- 4
- denoms
- counts
- group Id
- OG000
- value
- 1
- group Id
- OG001
- value
- 1
- group Id
- OG002
- value
- 1
- group Id
- OG003
- value
- 5
- group Id
- OG004
- value
- 1
- group Id
- OG005
- value
- 4
- group Id
- OG006
- value
- 7
- group Id
- OG007
- value
- 18
- group Id
- OG008
- value
- 3
- group Id
- OG009
- value
- 8
- group Id
- OG010
- value
- 1
- group Id
- OG011
- value
- 7
- units
- Participants
- title
- Hemoglobin, n=1,1,1,5,1,4,7,18,3,8,1,7,7,16,6
- categories
- measurements
- group Id
- OG000
- value
- 0
- group Id
- OG001
- value
- 0
- group Id
- OG003
- value
- 3
- group Id
- OG004
- value
- 1
- group Id
- OG005
- value
- 3
- group Id
- OG006
- value
- 4
- group Id
- OG007
- value
- 11
- group Id
- OG008
- value
- 2
- group Id
- OG009
- value
- 5
- group Id
- OG010
- value
- 1
- group Id
- OG011
- value
- 6
- group Id
- OG012
- value
- 3
- denoms
- counts
- group Id
- OG000
- value
- 1
- group Id
- OG001
- value
- 1
- group Id
- OG002
- value
- 0
- group Id
- OG003
- value
- 5
- group Id
- OG004
- value
- 1
- group Id
- OG005
- value
- 4
- group Id
- OG006
- value
- 7
- group Id
- OG007
- value
- 18
- group Id
- OG008
- value
- 3
- group Id
- OG009
- value
- 8
- group Id
- OG010
- value
- 1
- group Id
- OG011
- value
- 7
- units
- Participants
- title
- Lymphocytes, n=1,1,0,5,1,4,7,18,3,8,1,7,7,15,6
- categories
- measurements
- group Id
- OG000
- value
- 0
- group Id
- OG001
- value
- 0
- group Id
- OG003
- value
- 4
- group Id
- OG004
- value
- 0
- group Id
- OG005
- value
- 3
- group Id
- OG006
- value
- 1
- group Id
- OG007
- value
- 6
- group Id
- OG008
- value
- 2
- group Id
- OG009
- value
- 5
- group Id
- OG010
- value
- 0
- group Id
- OG011
- value
- 2
- group Id
- OG012
- value
- 5
- denoms
- counts
- group Id
- OG000
- value
- 1
- group Id
- OG001
- value
- 1
- group Id
- OG002
- value
- 0
- group Id
- OG003
- value
- 5
- group Id
- OG004
- value
- 1
- group Id
- OG005
- value
- 4
- group Id
- OG006
- value
- 7
- group Id
- OG007
- value
- 18
- group Id
- OG008
- value
- 3
- group Id
- OG009
- value
- 8
- group Id
- OG010
- value
- 1
- group Id
- OG011
- value
- 7
- units
- Participants
- title
- Neutrophils, n=1,1,0,5,1,4,7,18,3,8,1,7,7,15,5
- categories
- measurements
- group Id
- OG000
- value
- 0
- group Id
- OG001
- value
- 0
- group Id
- OG002
- value
- 1
- group Id
- OG003
- value
- 4
- group Id
- OG004
- value
- 1
- group Id
- OG005
- value
- 4
- group Id
- OG006
- value
- 4
- group Id
- OG007
- value
- 17
- group Id
- OG008
- value
- 3
- group Id
- OG009
- value
- 4
- group Id
- OG010
- value
- 1
- group Id
- OG011
- value
- 5
- denoms
- counts
- group Id
- OG000
- value
- 1
- group Id
- OG001
- value
- 1
- group Id
- OG002
- value
- 1
- group Id
- OG003
- value
- 5
- group Id
- OG004
- value
- 1
- group Id
- OG005
- value
- 4
- group Id
- OG006
- value
- 7
- group Id
- OG007
- value
- 18
- group Id
- OG008
- value
- 3
- group Id
- OG009
- value
- 8
- group Id
- OG010
- value
- 1
- group Id
- OG011
- value
- 7
- units
- Participants
- title
- Platelets, n=1,1,1,5,1,4,7,18,3,8,1,7,7,16,6
- categories
- measurements
- group Id
- OG000
- value
- 0
- group Id
- OG001
- value
- 0
- group Id
- OG002
- value
- 1
- group Id
- OG003
- value
- 4
- group Id
- OG004
- value
- 1
- group Id
- OG005
- value
- 3
- group Id
- OG006
- value
- 2
- group Id
- OG007
- value
- 9
- group Id
- OG008
- value
- 3
- group Id
- OG009
- value
- 4
- group Id
- OG010
- value
- 1
- group Id
- OG011
- value
- 3
- denoms
- counts
- group Id
- OG000
- value
- 1
- group Id
- OG001
- value
- 1
- group Id
- OG002
- value
- 1
- group Id
- OG003
- value
- 5
- group Id
- OG004
- value
- 1
- group Id
- OG005
- value
- 4
- group Id
- OG006
- value
- 7
- group Id
- OG007
- value
- 18
- group Id
- OG008
- value
- 3
- group Id
- OG009
- value
- 8
- group Id
- OG010
- value
- 1
- group Id
- OG011
- value
- 7
- units
- Participants
- title
- Leukocytes, n=1,1,1,5,1,4,7,18,3,8,1,7,7,16,6
- denoms
- counts
- group Id
- OG000
- value
- 1
- group Id
- OG001
- value
- 1
- group Id
- OG002
- value
- 1
- group Id
- OG003
- value
- 5
- group Id
- OG004
- value
- 1
- group Id
- OG005
- value
- 4
- group Id
- OG006
- value
- 7
- group Id
- OG007
- value
- 18
- group Id
- OG008
- value
- 3
- group Id
- OG009
- value
- 8
- group Id
- OG010
- value
- 1
- group Id
- OG011
- value
- 7
- units
- Participants
- description
- Blood samples were collected for the analysis of following hematology parameters: hemoglobin, lymphocytes, neutrophils, platelets and leukocytes. The laboratory parameters were graded according to NCI-CTCAE version 4.0. Grade 1: mild; Grade 2: moderate; Grade 3: severe or medically significant; Grade 4: life-threatening consequences; Grade 5: death related to AE. Higher grade indicates greater severity. An increase is defined as an increase in CTCAE grade relative to Baseline grade. Baseline was the most recent, non-missing value prior to or on the first study treatment dose date. Data for worst-case post Baseline with any grade increase is presented.
- groups
- description
- Participants were administered once daily oral dose of 5 milligrams (mg) GSK525762.
- id
- OG000
- title
- Part 1: GSK525762 5 mg QD
- description
- Participants were administered once daily oral dose of 10 mg GSK525762.
- id
- OG001
- title
- Part 1: GSK525762 10 mg QD
- description
- Participants were administered once daily oral dose of 20 mg GSK525762.
- id
- OG002
- title
- Part 1: GSK525762 20 mg QD
- description
- Participants with multiple myeloma (MM) were administered once daily oral dose of 30 mg GSK525762.
- id
- OG003
- title
- Part 1: GSK525762 30 mg QD MM
- description
- Participants were administered once daily oral dose of 40 mg GSK525762.
- id
- OG004
- title
- Part 1: GSK525762 40 mg QD
- description
- Participants with multiple myeloma were administered once daily oral dose of 40 mg GSK525762.
- id
- OG005
- title
- Part 1: GSK525762 40 mg QD MM
- description
- Participants with Acute Myeloid Leukemia (AML) were administered once daily oral dose of 60 mg GSK525762.
- id
- OG006
- title
- Part 1: GSK525762 60 mg QD AML
- description
- Participants with Non-Hodgkin's Lymphoma (NHL) were administered once daily oral dose of 60 mg GSK525762.
- id
- OG007
- title
- Part 1: GSK525762 60 mg QD NHL
- description
- Participants with MM were administered once daily oral dose of 60 mg GSK525762.
- id
- OG008
- title
- Part 1: GSK525762 60 mg QD MM
- description
- Participants with AML were administered once daily oral dose of 75 mg GSK525762.
- id
- OG009
- title
- Part 1: GSK525762 75 mg QD AML
- description
- Participants were administered once daily oral dose of 80 mg GSK525762.
- id
- OG010
- title
- Part 1: GSK525762 80 mg QD
- description
- Participants with AML were administered once daily oral dose of 80 mg GSK525762.
- id
- OG011
- title
- Part 1: GSK525762 80 mg QD AML
- param Type
- COUNT_OF_PARTICIPANTS
- population Description
- All Treated Population. Only those participants with data available at the specified data points were analyzed (represented by n=X in category titles).
- reporting Status
- POSTED
- time Frame
- Up to 86.9 weeks
- title
- Part 1: Number of Participants With Grade Change From Baseline in Hematology Parameters
- type
- PRIMARY
- unit Of Measure
- Participants
Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f
Preserved source evidence · Not medical advice